This information is intended for healthcare professionals based in Belgium and Luxembourg.
If you are not a healthcare professional, click here

Opdivo_Yervoy_Logo Opdivo_Yervoy_Logo Opdivo_Logo Opdivo_Chemotherapy_Logo

Neoadjuvant NSCLC

THE FIRST NEOADJUVANT IMMUNOTHERAPY IN NSCLC

View indication details

  • OPDIVO in combination with platinum-based chemotherapy is indicated for the neoadjuvant treatment of resectable non-small cell lung cancer at high risk of recurrence (stage II-IIIA disease according to the 7th edition AJCC/UICC) in adult patients whose tumours have PD-L1 expression ≥ 1%.
Expert opinion

Immunotherapy in
the resectable NSCLC setting

Educational meeting hosted by Prof Van Schil

CheckMate 816 study results

ECLIPSE webinar series for continuous I-O learning via live peer-to-peer clinical practice exchanges

Product information

OPDIVO + chemotherapy
in neoadjuvant NSCLC

Dosing scheme
OPDIVO
in neoadjuvant NSCLC

Practical user guide
based on OPDIVO SmPC

TNM Overview
Classification of Lung Tumors

PD-L1 testing
overview for OPDIVO

Patient & nurse materials

Patient brochure
with practical information
on immunotherapy

www.immunooncology.be

An informative website
on immunotherapy
for your nurses

Patient alert card

NSCLC, non small cell lung cancer; irAE(s), immune-related adverse event(s)